rfk jr glp-1 Jr. on coverage for medication, HHS cuts Can RFK Jr. Limit Ozempic

Weight loss is known to trigger compensatory biology: Increased appetite signaling Reduced resting energy expenditure Heightened food reward sensitivity Stopping GLP-1 therapy at peak dose, without tapering and without reinforcing lifestyle strategies at the exact moment hunger returns, does not allow lifestyle behaviors to take over. Emerging real-world data and obesity physiology suggest a different, more clinically relevant path: Gradual dose reduction rather than abrupt cessation Continued, structured dietary and exercise support Active monitoring during the high-risk post-cessation period We still need randomized trials designed specifically to test tapering and lifestyle-anchored maintenance strategies

Success!Keep reading, that's not how it turned out

Explore top weight loss programs featuring personalized plans and innovative GLP-1 medications like Ozempic and Wegovy

Explore the best Wegovy alternatives in 2026

Beyond their roles in diabetes treatment, AGIs have shown potential in extending lifespan and effectively treating aging-related diseases by modulating oxidative stress, gut microbiota, inflammatory responses, and nutrient-sensing pathways

The GLP-1 receptor agonist drug class has revolutionized obesity treatment, but key unmet needs persist